Fortrea Holdings Inc. reports news on its role as a global contract research organization serving the life sciences industry. The company provides phase I-IV clinical trial management, clinical pharmacology and consulting services for biopharmaceutical, biotechnology, medical device and diagnostic customers.
Recurring Fortrea updates include quarterly and annual financial results, book-to-bill trends, guidance, debt and capital actions, executive and board matters, equity award disclosures and technology used in clinical trial operations. Company announcements also cover platforms such as Fortrea Intelligent Technology and Xcellerate, which support trial workflow, oversight and site-facing processes.
Fortrea (FTRE) will release its third quarter 2026 financial results before the market opens on October 29, 2026. The company will host a conference call at 8:00 a.m. ET that day to discuss the results. A live webcast will be available at investors.fortrea.com, with a replay posted in the site's Events and Presentations section after the call.
Fortrea (FTRE) granted inducement equity awards under Nasdaq Listing Rule 5635(c)(4) on September 10, 2026, to five newly hired employees, including its new Chief Financial Officer, Jason Knoblauch.
The awards to Mr. Knoblauch comprise 106,755 performance share units (PSUs), which may vest at the end of a three-year period subject to specified performance goals, and 144,434 restricted stock units (RSUs) that vest in three equal annual installments from the grant date. Vesting of these awards generally requires his continuous employment, with the possibility of earlier vesting upon a change of control and certain termination events. All awards were approved by the independent directors and granted under Fortrea’s Amended and Restated 2025 Inducement Award Plan.
Fortrea (FTRE) will participate in three investor conferences in September 2026, featuring CEO Anshul Thakral, CFO Jason Knoblauch and SVP of Investor Relations Tracy Krumme.
Management will join a fireside chat and hold 1x1 and group meetings at the Baird 2026 Global Healthcare Conference in New York on September 15, 2026, from 2:00–2:30 p.m. EDT, with a live webcast and replay available via Fortrea’s Investor Relations “Events” page. They will also conduct 1x1 and group meetings at the Deutsche Bank 2026 Healthcare Summit in New York on September 16, 2026, and at the virtual RBC Pharma Services and Life Science Tools Conference on September 22, 2026. Investors seeking meetings are directed to contact their banking representatives.
Fortrea (FTRE) agreed on September 2, 2026 to acquire Worldwide Clinical Trials’ Early Phase Services division in an all-cash deal valued at approximately $45 million.
The transaction covers a 60,000 sq. ft. GLP bioanalytical lab in Austin, a 200-bed GCP-compliant clinical pharmacology unit in San Antonio, and a biospecimen storage facility in Pflugerville, Texas. These assets add in-house large and small molecule bioanalytical capabilities and expand Fortrea’s North American clinical research unit footprint, enabling more integrated, faster early-phase studies from first-in-human through proof-of-concept.
Early Phase Services will be integrated into Fortrea’s Clinical Pharmacology Services unit after closing, which is subject to regulatory and license approvals and final services agreements. Worldwide plans to focus investment on its rapidly growing late-stage business in oncology, neuroscience, internal medicine and rare disease, while both companies intend to maintain continuity for employees, customers and ongoing programs through strategic alliance and services agreements.
Fortrea (Nasdaq: FTRE) reported second quarter 2026 revenue of $678.2 million, down from $710.3 million in 2025, with a book-to-bill ratio of 1.06x and backlog of $7.8 billion. GAAP net loss was $(13.2) million, or $(0.14) per diluted share, versus a prior-year loss of $(374.9) million that included a large goodwill impairment.
Adjusted net income was $22.7 million (EPS $0.23) and adjusted EBITDA was $58.7 million, both above 2025 levels. First-half 2026 adjusted EBITDA reached $105.7 million. Cash from operations in Q2 was $28.9 million and free cash flow $19.9 million. Fortrea increased full-year 2026 guidance to revenue of $2,620–$2,690 million and adjusted EBITDA of $205–$220 million, reflecting management’s higher outlook for the year.
Fortrea (Nasdaq: FTRE) will release its second quarter 2026 financial results before the market opens on Wednesday, July 29, 2026. The company will host a conference call at 8:00 a.m. ET that same day to discuss the results, with access via pre-registration for dial-in details and a unique PIN, and a live webcast and replay available at investors.fortrea.com.
Fortrea (Nasdaq: FTRE) appointed Jason Knoblauch as chief financial officer, effective July 6, 2026, succeeding Jill McConnell, who will support a smooth transition.
The company reaffirmed its full-year 2026 guidance, targeting revenue of $2,550–$2,650 million and adjusted EBITDA of $190–$220 million.
Fortrea (Nasdaq: FTRE) granted an inducement award of 240,500 restricted stock units (RSUs) on June 10, 2026 to 10 newly hired employees.
The RSUs vest in three equal annual installments starting June 10, 2027, under the 2025 Inducement Award Plan and in line with Nasdaq Listing Rule 5635(c)(4).
Fortrea (Nasdaq: FTRE) will participate in the Jefferies Global Healthcare Conference/b) in New York.CEO Anshul Thakral, CFO Jill McConnell, and SVP of Investor Relations Tracy Krumme will join a fireside chat on Thursday, June 4, 2026 at 8:45 AM EDT, with a live webcast and replay available.
Fortrea (Nasdaq: FTRE) reported first-quarter 2026 results with revenue of $636.5 million, GAAP net loss of $23.6 million (loss per diluted share $0.25), adjusted net income of $15.2 million (adjusted EPS $0.16) and adjusted EBITDA of $47.0 million. Backlog was $7,846 million and book-to-bill was 1.15x. The company affirmed full-year 2026 guidance of $2,550–$2,650 million revenue and $190–$220 million adjusted EBITDA.
The company will host an earnings call on May 5, 2026, with a replay and supplemental slides available on its Investor Relations website.